Third Harmonic Bio, Inc.THRDNASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
1.02%
↓ 91% below average
Average (16q)
11.18%
Historical baseline
Range
High:94.60%
Low:-32.69%
Volatility
1138.5%
High variability
| Period | Value |
|---|---|
| Q1 2025 | 1.02% |
| Q4 2024 | -7.11% |
| Q3 2024 | 35.13% |
| Q2 2024 | 34.82% |
| Q1 2024 | 5.20% |
| Q4 2023 | -0.85% |
| Q3 2023 | 11.78% |
| Q2 2023 | -20.74% |
| Q1 2023 | -27.22% |
| Q4 2022 | 94.60% |
| Q3 2022 | 13.78% |
| Q2 2022 | -32.69% |
| Q1 2022 | 44.97% |
| Q4 2021 | -12.85% |
| Q3 2021 | 50.23% |
| Q2 2021 | 0.00% |
| Q1 2021 | 0.00% |